UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Andrea Kokorovic; Alan I. So; Hosam Serag; Christopher French; Robert J. Hamilton; Jason P. Izard; Jasmir G. Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A. Rendon

doi:10.5489/cuaj.8054

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies

Andrea Kokorovic, Alan I. So, Hosam Serag, Christopher French, Robert J. Hamilton, Jason P. Izard, Jasmir G. Nayak, Frédéric Pouliot, Fred Saad, Bobby Shayegan, Armen Aprikian, Ricardo A. Rendon

科研成果: 期刊稿件 › 文章 › 同行评审

7 引用（Scopus）

源语言	英语
页（从-至）	E416-E431
期刊	Journal of the Canadian Urological Association
卷	16
期	8
DOI	https://doi.org/10.5489/cuaj.8054
出版状态	已出版 - 8月 2022
已对外发布	是

!!!ASJC Scopus Subject Areas

泌尿学

访问文件

10.5489/cuaj.8054

其它文件与链接

引用此

Kokorovic, A., So, A. I., Serag, H., French, C., Hamilton, R. J., Izard, J. P., Nayak, J. G., Pouliot, F., Saad, F., Shayegan, B., Aprikian, A., & Rendon, R. A. (2022). UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Journal of the Canadian Urological Association, 16(8), E416-E431. https://doi.org/10.5489/cuaj.8054

Kokorovic, A, So, AI, Serag, H, French, C, Hamilton, RJ, Izard, JP, Nayak, JG, Pouliot, F, Saad, F, Shayegan, B, Aprikian, A & Rendon, RA 2022, 'UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies', Journal of the Canadian Urological Association, 卷 16, 号码 8, 页码 E416-E431. https://doi.org/10.5489/cuaj.8054

@article{874a9805b22d46a6a60c53c887a210b2,

title = "UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies",

author = "Andrea Kokorovic and So, {Alan I.} and Hosam Serag and Christopher French and Hamilton, {Robert J.} and Izard, {Jason P.} and Nayak, {Jasmir G.} and Fr{\'e}d{\'e}ric Pouliot and Fred Saad and Bobby Shayegan and Armen Aprikian and Rendon, {Ricardo A.}",

note = "Funding Information: Competing interests: Dr. So has been an advisory board member for AbbVie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Izard has received a grant(s) or honoraria from AbbVie, Astellas, Bayer, Ferring, Janssen, and Sanofi; and has participated in clinical trials supported by AbbVie, Astellas, AstraZeneca, Bayer, Janssen, and Merck. Dr. Saad has been an advisory board member for and has received payment/honoraria from AbbVie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Aprikian has been an advisory board member for AbbVie, Astellas, and Bayer; and has received grants from AbbVie, Astellas Bayer, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers{\textquoteright} bureau member for and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. The remaining authors report no competing personal or financial interests related to this work. The remaining authors report no competing personal or financial interests related to this work.",

year = "2022",

month = aug,

doi = "10.5489/cuaj.8054",

language = "English",

volume = "16",

pages = "E416--E431",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "8",

}

TY - JOUR

T1 - UPDATE - Canadian Urological Association guideline on androgen deprivation therapy

T2 - Adverse events and management strategies

AU - Kokorovic, Andrea

AU - So, Alan I.

AU - Serag, Hosam

AU - French, Christopher

AU - Hamilton, Robert J.

AU - Izard, Jason P.

AU - Nayak, Jasmir G.

AU - Pouliot, Frédéric

AU - Saad, Fred

AU - Shayegan, Bobby

AU - Aprikian, Armen

AU - Rendon, Ricardo A.

N1 - Funding Information: Competing interests: Dr. So has been an advisory board member for AbbVie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Izard has received a grant(s) or honoraria from AbbVie, Astellas, Bayer, Ferring, Janssen, and Sanofi; and has participated in clinical trials supported by AbbVie, Astellas, AstraZeneca, Bayer, Janssen, and Merck. Dr. Saad has been an advisory board member for and has received payment/honoraria from AbbVie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Aprikian has been an advisory board member for AbbVie, Astellas, and Bayer; and has received grants from AbbVie, Astellas Bayer, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. The remaining authors report no competing personal or financial interests related to this work. The remaining authors report no competing personal or financial interests related to this work.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85136227973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136227973&partnerID=8YFLogxK

U2 - 10.5489/cuaj.8054

DO - 10.5489/cuaj.8054

M3 - Article

AN - SCOPUS:85136227973

SN - 1911-6470

VL - 16

SP - E416-E431

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 8

ER -